Advanced Clinical Development and Licensure of a Adjuvanted Egg-based Influenza Vaccine (AdjEgg)

Request for Proposal Description

The objective of this RPP is to advance the development of a sustainable, adjuvanted, egg-based pandemic influenza vaccine candidate through manufacturing and early clinical development, with the potential for pivotal clinical evaluation and FDA licensure. The effort also aims to establish commercially sustainable manufacturing capabilities to support pandemic influenza preparedness and response.

Submission Information

All RRPV submissions must be submitted to the BARDA Digital Resources (BDR) RRPV Portal.

The account request process is simple but may take several days for approval and access. To request a BDR RRPV Portal account (first-time user), please complete the BDR Access Request Form. If you already have an account, please ensure you have access several days ahead of the submission deadline, if you have difficulty accessing your account please reach out to [email protected].

Documentation and reference materials for the BDR RRPV Portal are available to RRPV Member Organizations from the RRPV Members Only Site (for new users, request access here), and upon request from [email protected].

Neither the Government nor the RRPV CMF will make allowances/exceptions for submission problems encountered by the Offeror using system-to-system interfaces. If the Offeror fails to submit the full submission prior to the deadline, the submission may not be accepted. It is the Offeror’s responsibility to ensure a timely and complete submission. Failure to propose your submission on time for any reason may result in the submission not being considered for award.

Solicitation Details

Original RPP Release:

Issued: 20 November 2026

Questions Due: 11 December 2026 12PM ET

Proposals Due: 25 January 2027 by 1PM ET